Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Science Board's Report: Legislative Negotiating Tactic, Or Just Whining For Money?

Executive Summary

21st Century Cures criticized by FDA advisors for unfunded mandates, but legislation also represents best near-term prospect for reforms of the kind the report envisions.

You may also be interested in...



US FDA Progress Report Highlights Biomarkers, Continuous Manufacturing, Antibiotic Testing

Agency documents its regulatory science accomplishments to advance product development and manufacturing and ensure the safety and effectiveness of marketed products.

FDA Relocates To Lake Wobegon? Most Applications Deemed Above Average, Researchers Find

Studies cite routine use of special review programs for drugs that are not first in class and less rigorous requirements for approval of supplemental applications.

Science Evolution At FDA ‘Transformative,’ Advisors Say

An FDA Science Board subcommittee report finds industry and researcher perceptions of FDA's science readiness has improved over the past eight years. But the agency still faces major challenges tied to the current speed of scientific and technical progress.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS057159

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel